Literature DB >> 28956184

Reliable diagnosis of IDH-mutant glioblastoma by 2-hydroxyglutarate detection: a study by 3-T magnetic resonance spectroscopy.

Manabu Natsumeda1, Kunio Motohashi1,2, Hironaka Igarashi3, Takanori Nozawa1,4, Hideaki Abe1, Yoshihiro Tsukamoto1, Ryosuke Ogura1, Masayasu Okada1, Tsutomu Kobayashi1, Hiroshi Aoki1, Hitoshi Takahashi4, Akiyoshi Kakita4, Kouichirou Okamoto1,2, Tsutomu Nakada2, Yukihiko Fujii1.   

Abstract

We have previously reported that reliable detection of 2-hydroxyglutarate (2HG) in isocitrate dehydrogenase (IDH)-mutant WHO grade 2 and 3 gliomas is possible utilizing 3.0-T single-voxel magnetic resonance spectroscopy (SVMRS). We set out to determine whether the same method could be applied to detect 2HG in IDH-mutant glioblastoma. Forty-four patients harboring glioblastoma underwent pre-operative MRS evaluation to detect 2HG and other metabolites. Presence of IDH-mutations was determined by IDH1 R132H immunohistochemical analysis and DNA sequencing of surgically obtained tissues. Six out of 44 (13.6%) glioblastomas were IDH-mutant. IDH-mutant glioblastoma exhibited significantly higher accumulation of 2HG (median 3.191 vs. 0.000 mM, p < 0.0001, Mann-Whitney test). A cutoff of 2HG = 0.897 mM achieved high sensitivity (100.0%) and specificity (92.59%) in determining IDH-mutation in glioblastoma. Glioblastoma with high 2HG accumulation did not have significantly longer overall survival than glioblastoma with low 2HG accumulation (p = 0.107, log-rank test). Non-invasive and reliable detection of 2HG in IDH-mutant glioblastoma was possible by 3.0-T SVMRS.

Entities:  

Keywords:  2-Hydroxyglutarate; Glioblastoma; IDH mutation; Magnetic resonance spectroscopy

Mesh:

Substances:

Year:  2017        PMID: 28956184     DOI: 10.1007/s10143-017-0908-y

Source DB:  PubMed          Journal:  Neurosurg Rev        ISSN: 0344-5607            Impact factor:   3.042


  27 in total

Review 1.  Detection of oncogenic IDH1 mutations using magnetic resonance spectroscopy of 2-hydroxyglutarate.

Authors:  Ovidiu C Andronesi; Otto Rapalino; Elizabeth Gerstner; Andrew Chi; Tracy T Batchelor; Dan P Cahill; A Gregory Sorensen; Bruce R Rosen
Journal:  J Clin Invest       Date:  2013-09-03       Impact factor: 14.808

2.  Inhibition of glutaminase preferentially slows growth of glioma cells with mutant IDH1.

Authors:  Meghan J Seltzer; Bryson D Bennett; Avadhut D Joshi; Ping Gao; Ajit G Thomas; Dana V Ferraris; Takashi Tsukamoto; Camilo J Rojas; Barbara S Slusher; Joshua D Rabinowitz; Chi V Dang; Gregory J Riggins
Journal:  Cancer Res       Date:  2010-11-02       Impact factor: 12.701

Review 3.  Interrogating IDH Mutation in Brain Tumor: Magnetic Resonance and Hyperpolarization.

Authors:  Jingzhe Hu; Travis C Salzillo; Napapon Sailasuta; Frederick F Lang; Pratip Bhattacharya
Journal:  Top Magn Reson Imaging       Date:  2017-02

4.  2-hydroxyglutarate as a magnetic resonance biomarker for glioma subtyping.

Authors:  Morteza Esmaeili; Riyas Vettukattil; Tone Frost Bathen
Journal:  Transl Oncol       Date:  2013-04-01       Impact factor: 4.243

5.  Immunohistochemical profiles of IDH1, MGMT and P53: practical significance for prognostication of patients with diffuse gliomas.

Authors:  Ryosuke Ogura; Yoshihiro Tsukamoto; Manabu Natsumeda; Mizuho Isogawa; Hiroshi Aoki; Tsutomu Kobayashi; Seiichi Yoshida; Kouichiro Okamoto; Hitoshi Takahashi; Yukihiko Fujii; Akiyoshi Kakita
Journal:  Neuropathology       Date:  2015-05-06       Impact factor: 1.906

6.  An integrated genomic analysis of human glioblastoma multiforme.

Authors:  D Williams Parsons; Siân Jones; Xiaosong Zhang; Jimmy Cheng-Ho Lin; Rebecca J Leary; Philipp Angenendt; Parminder Mankoo; Hannah Carter; I-Mei Siu; Gary L Gallia; Alessandro Olivi; Roger McLendon; B Ahmed Rasheed; Stephen Keir; Tatiana Nikolskaya; Yuri Nikolsky; Dana A Busam; Hanna Tekleab; Luis A Diaz; James Hartigan; Doug R Smith; Robert L Strausberg; Suely Kazue Nagahashi Marie; Sueli Mieko Oba Shinjo; Hai Yan; Gregory J Riggins; Darell D Bigner; Rachel Karchin; Nick Papadopoulos; Giovanni Parmigiani; Bert Vogelstein; Victor E Velculescu; Kenneth W Kinzler
Journal:  Science       Date:  2008-09-04       Impact factor: 47.728

7.  2-hydroxyglutarate detection by magnetic resonance spectroscopy in IDH-mutated patients with gliomas.

Authors:  Changho Choi; Sandeep K Ganji; Ralph J DeBerardinis; Kimmo J Hatanpaa; Dinesh Rakheja; Zoltan Kovacs; Xiao-Li Yang; Tomoyuki Mashimo; Jack M Raisanen; Isaac Marin-Valencia; Juan M Pascual; Christopher J Madden; Bruce E Mickey; Craig R Malloy; Robert M Bachoo; Elizabeth A Maher
Journal:  Nat Med       Date:  2012-01-26       Impact factor: 53.440

8.  Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of α-ketoglutarate-dependent dioxygenases.

Authors:  Wei Xu; Hui Yang; Ying Liu; Ying Yang; Ping Wang; Se-Hee Kim; Shinsuke Ito; Chen Yang; Pu Wang; Meng-Tao Xiao; Li-xia Liu; Wen-qing Jiang; Jing Liu; Jin-ye Zhang; Bin Wang; Stephen Frye; Yi Zhang; Yan-hui Xu; Qun-ying Lei; Kun-Liang Guan; Shi-min Zhao; Yue Xiong
Journal:  Cancer Cell       Date:  2011-01-18       Impact factor: 38.585

9.  IDH mutations predict longer survival and response to temozolomide in secondary glioblastoma.

Authors:  Qi SongTao; Yu Lei; Gui Si; Ding YanQing; Han HuiXia; Zhang XueLin; Wu LanXiao; Yao Fei
Journal:  Cancer Sci       Date:  2011-11-28       Impact factor: 6.518

10.  Isocitrate dehydrogenase-1 mutations as prognostic biomarker in glioblastoma multiforme patients in West Bohemia.

Authors:  J Polivka; J Polivka; V Rohan; M Pesta; T Repik; P Pitule; O Topolcan
Journal:  Biomed Res Int       Date:  2014-01-09       Impact factor: 3.411

View more
  6 in total

1.  Comparative Value of 2-Hydroxyglutarate-to-Lipid and Lactate Ratio versus 2-Hydroxyglutarate Concentration on MR Spectroscopic Images for Predicting Isocitrate Dehydrogenase Mutation Status in Gliomas.

Authors:  Chong Hyun Suh; Ho Sung Kim; Ji Eun Park; Seung Chai Jung; Choong Gon Choi; Dong-Cheol Woo; Ho Beom Lee; Sang Joon Kim
Journal:  Radiol Imaging Cancer       Date:  2020-07-31

Review 2.  Standard clinical approaches and emerging modalities for glioblastoma imaging.

Authors:  Joshua D Bernstock; Sam E Gary; Neil Klinger; Pablo A Valdes; Walid Ibn Essayed; Hannah E Olsen; Gustavo Chagoya; Galal Elsayed; Daisuke Yamashita; Patrick Schuss; Florian A Gessler; Pier Paolo Peruzzi; Asim K Bag; Gregory K Friedman
Journal:  Neurooncol Adv       Date:  2022-05-26

3.  Fluid attenuation in non-contrast-enhancing tumor (nCET): an MRI Marker for Isocitrate Dehydrogenase (IDH) mutation in Glioblastoma.

Authors:  Sohil H Patel; Prem P Batchala; Thomas J Eluvathingal Muttikkal; Sergio S Ferrante; James T Patrie; Camilo E Fadul; David Schiff; M Beatriz Lopes; Rajan Jain
Journal:  J Neurooncol       Date:  2021-03-04       Impact factor: 4.130

4.  2-Hydroxyglutarate MR spectroscopy for prediction of isocitrate dehydrogenase mutant glioma: a systemic review and meta-analysis using individual patient data.

Authors:  Chong Hyun Suh; Ho Sung Kim; Seung Chai Jung; Choong Gon Choi; Sang Joon Kim
Journal:  Neuro Oncol       Date:  2018-11-12       Impact factor: 13.029

5.  Magnetic resonance spectroscopy for the study of cns malignancies.

Authors:  Victor Ruiz-Rodado; Jeffery R Brender; Murali K Cherukuri; Mark R Gilbert; Mioara Larion
Journal:  Prog Nucl Magn Reson Spectrosc       Date:  2020-12-02       Impact factor: 9.795

Review 6.  Magnetic resonance spectroscopy of isocitrate dehydrogenase mutated gliomas: current knowledge on the neurochemical profile.

Authors:  Francesca Branzoli; Małgorzata Marjańska
Journal:  Curr Opin Neurol       Date:  2020-08       Impact factor: 6.283

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.